Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, Fukuoka, 812-8582, Japan.
Int J Clin Oncol. 2020 Jul;25(7):1318-1326. doi: 10.1007/s10147-020-01672-3. Epub 2020 Apr 11.
Adjuvant chemotherapy is generally recommended for patients with stage III colorectal cancer. Even with adjuvant chemotherapy, 20-30% of such patients develop recurrences; the risk factors for recurrence are currently unclear. The preoperative systemic inflammation index has been linked to poor prognoses in patients with colorectal cancer; however, the relationship between postoperative systemic inflammation index and recurrence is unclear. We aimed to evaluate the association between preoperative and postoperative systemic inflammation indexes and recurrence in patients with stage III colorectal cancer.
The following laboratory data of 133 patients with stage III colorectal cancer were analyzed: preoperative and postoperative C-reactive protein/albumin ratios (CAR); neutrophil to lymphocyte ratios (NLR); and platelet to lymphocyte ratios (PLR) and their relationships with recurrence analyzed.
The optimal cutoff values for systemic inflammation indexes were determined by examining receiver operating characteristic curves. Multivariate analyses indicated that N-stage, postoperative complications, preoperative NLR, and postoperative CAR were independent predictors of recurrence-free survival (RFS). Postoperative CAR was also an independent predictor of overall survival (OS). Patients with postoperative CAR ≥ 0.035 who did not receive adjuvant chemotherapy had shorter RFS and OS than those who did. There were no significant differences in RFS and OS between patients with postoperative CAR < 0.035 who did and did not receive adjuvant chemotherapy.
Postoperative CAR is strongly associated with poor prognosis in patients with stage III colorectal cancer and is a useful biomarker for determining whether adjuvant chemotherapy should be administered.
辅助化疗通常推荐用于 III 期结直肠癌患者。即使接受辅助化疗,仍有 20-30%的此类患者出现复发;复发的危险因素目前尚不清楚。术前全身炎症指数与结直肠癌患者的不良预后相关;然而,术后全身炎症指数与复发之间的关系尚不清楚。我们旨在评估 III 期结直肠癌患者术前和术后全身炎症指数与复发之间的关系。
分析了 133 例 III 期结直肠癌患者的以下实验室数据:术前和术后 C 反应蛋白/白蛋白比值(CAR);中性粒细胞与淋巴细胞比值(NLR);血小板与淋巴细胞比值(PLR),并分析其与复发的关系。
通过检查接受者操作特征曲线确定了全身炎症指数的最佳截断值。多变量分析表明,N 期、术后并发症、术前 NLR 和术后 CAR 是无复发生存(RFS)的独立预测因素。术后 CAR 也是总生存(OS)的独立预测因素。未接受辅助化疗且术后 CAR≥0.035 的患者的 RFS 和 OS 短于接受辅助化疗的患者。术后 CAR<0.035 且接受和未接受辅助化疗的患者的 RFS 和 OS 无显著差异。
术后 CAR 与 III 期结直肠癌患者的不良预后密切相关,是决定是否应给予辅助化疗的有用生物标志物。